Načítá se...
The role of novel immunotherapies in non-Hodgkin lymphoma
Immunotherapy is an evolving modality in the treatment of non-Hodgkin lymphoma. Vaccinations with patient-specific tumor-derived antigens have been developed to strengthen immune response to tumor. The success of rituximab, a monoclonal antibody for CD20 on malignant B-cells, fueled further immunoth...
Uloženo v:
| Vydáno v: | Transl Cancer Res |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5612371/ https://ncbi.nlm.nih.gov/pubmed/28955654 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tcr.2017.01.08 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|